Alto vs Hims & Hers

Side-by-side comparison of AI visibility scores, market position, and capabilities

Hims & Hers leads in AI visibility (86 vs 57)
Alto logo

Alto

ChallengerHealthcare

Online Pharmacy

Digital pharmacy with same-day delivery and transparent price comparison; concierge mobile app experience competing with Amazon Pharmacy and Capsule for urban medication delivery.

AI VisibilityBeta
Overall Score
C57
Category Rank
#144 of 596
AI Consensus
86%
Trend
stable
Per Platform
ChatGPT
54
Perplexity
57
Gemini
54

About

Alto Pharmacy is a digital pharmacy providing prescription delivery service with a concierge pharmacy experience — offering same-day or next-day delivery of prescriptions to customers' homes, transparent pricing (showing the lowest cost option including GoodRx discounts, insurance, or cash pay), and dedicated pharmacist support through the Alto mobile app. Founded in 2015 by Mattieu Gamache-Asselin and Jamie Karraker in San Francisco, Alto has raised approximately $350 million and operates in major US markets including San Francisco, Los Angeles, New York, Houston, and Denver.\n\nAlto's model combines an app-based pharmacy experience with local courier delivery infrastructure — customers transfer their prescriptions to Alto, and a courier delivers medications within hours. The app shows real-time prescription status, communicates with pharmacists through chat, and automatically compares pricing across insurance, manufacturer coupons, and GoodRx discounts to ensure the customer pays the lowest price. Proactive refill management and automatic renewal outreach reduce the friction of managing chronic medications.\n\nIn 2025, Alto competes with Amazon Pharmacy (backed by Amazon's logistics and Prime), Capsule (acquired by NovaBay Pharmaceuticals), PillPack (Amazon), Walgreens and CVS app-based delivery for on-demand pharmacy delivery. The retail pharmacy market is consolidating — independent pharmacies face PBM reimbursement pressure and CVS/Walgreens have been closing unprofitable locations. Alto's model of app + courier delivery + price transparency resonates with urban tech consumers. The 2025 strategy focuses on expanding specialty pharmacy capabilities (high-cost biologics and specialty medications that require complex handling), growing in new geographic markets, and deepening integrations with healthcare providers for seamless prescribing-to-delivery workflows.

Full profile
Hims & Hers logo

Hims & Hers

EmergingHealthcare

Telehealth Pharmacy

Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.

AI VisibilityBeta
Overall Score
A86
Category Rank
#8 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
88
Perplexity
92
Gemini
83

About

Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.

Full profile

AI Visibility Head-to-Head

57
Overall Score
86
#144
Category Rank
#8
86
AI Consensus
79
stable
Trend
stable
54
ChatGPT
88
57
Perplexity
92
54
Gemini
83
52
Claude
90
51
Grok
89

Key Details

Category
Online Pharmacy
Telehealth Pharmacy
Tier
Challenger
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Alto
Online Pharmacy
Only Hims & Hers
Telehealth Pharmacy

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.